ClinicalTrials.gg
CompletedNCT02821416ARIAUpdated Jan 7, 2021Results posted

Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics

A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 6 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
28th of 39
46 · median 128
Started
2016
with 4 others
Phase 3
20 of 39
1 open now
Registered
16th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 28th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 16th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.

Read the detailed description

This randomized, double-blind, parallel group, placebo-controlled study will evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks for 3 doses on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.

Approximately 38 non-smoking men and women (18 - 65 years of age) corticosteroid-free (oral and inhaled) mild, atopic asthmatics who have demonstrated a dual (early and late) asthmatic response to inhaled allergen challenge at screening will be recruited to complete the study.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures
  2. Female or male aged 18 to 65 years, inclusively, at the time of enrolment.
  3. General good health
  4. Mild, stable, allergic asthma and asthma therapy limited to inhaled, short-acting beta 2 agonists (not more than twice weekly)
  5. Positive skin-prick test to at least one common aeroallergen

Exclusion criteria

Exclusion Criteria:

  1. Current lung disease other than mild allergic asthma
  2. Any history or symptoms of disease, including, but not limited to, cardiovascular, neurologic, or haematologic
  3. Any abnormal findings in laboratory test results in complete blood count, coagulation, chemistry panel and urinalysis at enrolment and during screening period
  4. History of anaphylaxis to any biologic therapy or vaccine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Benralizumab administered subcutaneously

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously

    Other: Placebo

Interventions

  • BiologicalBenralizumab

    Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive

  • OtherPlacebo

    Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive

06

What researchers measure

Primary outcomes

  1. Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge

    To evaluate the effect of benralizumab on allergen-induced increases in eosinophils in induced sputum

    Time frame: From prechallenge to 7 hours post allergen challenge during week 9

  2. Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge

    To evaluate the effect of benralizumab on the allergen-induced late (3-7 hours post challenge) asthmatic response (LAR)

    Time frame: From prechallenge to 3 to 7 hours post allergen challenge during week 9

07

Results

Posted Jan 7, 2021
Limitations and caveats
This allergen challenge study was conducted in a mild, atopic asthma patient population, distinct from the current approved severe eosinophilic asthma indication.

Participant flow

Participant flow — Overall Study
MilestoneBenra 30mg q.4 WeekPlacebo
Started2323
Completed2022
Not completed31
Withdrew: Adverse event01
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up10

Outcome measures

PrimaryChange in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge

To evaluate the effect of benralizumab on allergen-induced increases in eosinophils in induced sputum

Time frame:
From prechallenge to 7 hours post allergen challenge during week 9
Reported as:
Mean · Percent
Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge
PercentBenra 30mg q.4 WeeksPlacebo
Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge0.822 ± 4.0546.468 ± 9.560
Statistical analysis
  • Benra 30mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.0208 · Median difference (final values): -5.81 · 95% CI -10.69 to -0.94Model includes covariates of treatment, time post-allergen challenge , treatment\*time post-allergen challenge, allergen induced at screening
PrimaryMaximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge

To evaluate the effect of benralizumab on the allergen-induced late (3-7 hours post challenge) asthmatic response (LAR)

Time frame:
From prechallenge to 3 to 7 hours post allergen challenge during week 9
Reported as:
Mean · Percent
Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge
PercentBenra 30mg q.4 WeeksPlacebo
Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge15.152 ± 8.83416.275 ± 10.235
Statistical analysis
  • Benra 30mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.3630 · Median difference (final values): 2.535 · 95% CI -3.045 to 8.116Model includes covariates of treatment, maximum percent decrease in FEV1 late asthma response

Adverse events

Collected over From Visit 1a to Visit 17. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30mg q.4 Week0/23 (0%)0/23 (0%)7/23 (30.4%)
Placebo0/23 (0%)0/23 (0%)14/23 (60.9%)
Most frequent other events
Showing 10 of 38
Most frequent other events
EventBenra 30mg q.4 WeekPlacebo
NasopharyngitisInfections and infestations1/233/23
HeadacheNervous system disorders1/233/23
BronchitisInfections and infestations0/232/23
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/232/23
CyanosisCardiac disorders0/231/23
VomitingGastrointestinal disorders0/231/23
Catheter site haematomaGeneral disorders0/231/23
Injection site painGeneral disorders1/230/23
MalaiseGeneral disorders0/231/23
Vessel puncture site painGeneral disorders0/231/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benra 30mg q.4 WeekPlaceboTotal
Mean30.4 ± 12.331.5 ± 13.330.9 ± 12.7
Age, Customized
Age, Customized(Participants)Benra 30mg q.4 WeekPlaceboTotal
>=18 - <=50202040
>50 - <=65336
>65 - <=75000
Sex: Female, Male
Sex: Female, Male(Participants)Benra 30mg q.4 WeekPlaceboTotal
Female142034
Male9312
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benra 30mg q.4 WeekPlaceboTotal
White161935
Black or African American000
Asian639
Other112
08

Study locations

6 sites
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Edmonton, Alberta T6G 2B7, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Research Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Research Site
    Quebec, G1V 4G5, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Oct 2019, 36 months.

Results were first posted in Jan 2021, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 36 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2016
First posted
Jul 1, 2016
StartActual
Oct 11, 2016
Primary completionActual
Oct 22, 2019
CompletionActual
Oct 22, 2019
Results first posted
Jan 7, 2021
Last update
Jan 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02821416
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 1, 2016
Start date
Oct 11, 2016
Primary completion
Oct 22, 2019
Completion
Oct 22, 2019
Results posted
Jan 7, 2021
Last update
Jan 7, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion